Assessing Aortic Valve Calcification May Help Predict Paravalvular Leak After TAVR

 

 

Download this article's Factoid (PDF & PPT for Gold Subscribers)

The presence of valve calcification increases the odds of at least mild paravalvular regurgitation after transcatheter aortic valve replacement (TAVR), according to a study published in the August 2014 issue of JACC: Cardiovascular Interventions. Moreover, the authors suggest that asymmetry of the annulus and left ventricular outflow tract (LVOT) may better predict the need for postdilatation than that of the leaflets.

Methods
Researchers led by Susheel K. Kodali, MD, of Columbia University Medical Center (New York, NY), studied 150 patients (mean age 83.3 years and 54% women) undergoing TAVR with either the Sapien or Sapien XT valves (Edwards Lifesciences; Irvine, CA) at their institution from October 2011 through July 2013.
Calculated aortic valve area was 0.66 ± 0.17 cm2 and peak velocity 4.0 ± 0.7 m/s. Transfemoral TAVR was the most common strategy (83%), with 9% of patients receiving transaortic and 8% transapical procedures. Postdilatation was performed in 25% of the cohort. 
Total valve calcification and asymmetrical calcification in the leaflet, annulus, LVOT, and combined annulus/LVOT regions was assessed via multislice CT.


Among the 69 patients (46%) with paravalvular regurgitation at the end of the procedure, 6% had moderate (10 to 19 mm2), 13% had mild (5 to 9 mm2), and 27% had trace amounts (0 to 4 mm2). No patient had severe regurgitation. Patients with at least mild regurgitation had more calcification in all regions than those with less or no paravalvular leak. Similarly, those who received postdilatation showed more calcification in all regions than those without postdilatation. 

In addition, more asymmetry was seen in all regions in patients who had postdilatation (P < .01 for all) and—with the exception of the leaflet—in those with at least mild leak (19%; table 1).

Table 1. Asymmetry of Calcium Volume

 

No/Trace Paravalvular Regurgitation

At Least Mild Paravalvular Regurgitation

P Value

LVOT, mm3

30 ± 69

65 ± 81

.013

Annulus, mm3

67 ± 64

125 ± 101

.002

Annulus/LVOT, mm3

79 ± 87

152 ± 126

.002

Leaflet, mm3

276 ± 209

304 ± 185

.243

 

Aortic calcification was further shown to predict mild or higher paravalvular leak in all regions except the leaflet in ROC analysis (table 2). 

Table 2. ROC Analysis: Calcification Predicting At Least Mild Leak

 

Area Under the Curve

Cutoff (mm3)

P Value

LVOT

0.648

17.6

.017

Annulus

0.687

19.9

.002

Annulus/LVOT

0.689

69.9

.0015

Leaflet

0.571

NS

.252

 

Multivariable analysis identified calcification in each of the 3 regions as independent predictors of mild or greater paravalvular leak and postdilatation (P < .0001 for all). 

In a telephone interview with TCTMD, coauthor Omar K. Khalique, MD, also of Columbia University Medical Center, said that paravalvular leak is still “poorly understood.” 

Even though leaflet calcification did not seem to be as important as calcification in the other aortic regions in the study, it should be studied further because “the leaflets may indirectly impact the overall deployment of the valve in terms of inhibiting the [optimal] position,…which may also lead to paravalvular leak in an indirect way,” he continued.

The overall take-home message, Dr. Khalique said, “is that when you have significant calcification, you can expect paravalvular regurgitation…. It won't stop you from doing the case necessarily, but it gives you a good way to know what to expect and plan.” 

A ‘Triple-Edged Sword’  

Peter C. Block, MD, of Emory University School of Medicine (Atlanta, GA), told TCTMD in a telephone interview that it is common knowledge that severe LVOT calcification centered in the leaflets makes it much more difficult to perform successful TAVR and achieve an appropriate seal, although the study is the first to quantify this. 

However, this issue becomes a kind of “triple-edged sword,” he commented. 

“You need the calcification in order to anchor the valve, but…without calcification, you would probably get a much better seal” and so less paravalvular regurgitation, he explained. In the presence of severe calcification in the LVOT or leaflets, surgery might be the best option, he continued, “but many of these patients truly cannot be operated on.”

The ultimate unanswered question, he said, is: “Given the improvement that you know you can achieve with [TAVR] in patients with severe calcification, is the benefit of relieving the stenosis worth the detriment of having a paravalvular leak?”

In an accompanying editorial, Paolo Raggi, MD, of the University of Alberta (Edmonton, Canada), agrees. “Once again, the ever-correct conclusion is that a careful selection of the most suitable patient for the most appropriate procedure is the desirable way to proceed,” he writes. Still, the study fails to indicate “‘how much is too much,’ that is, a threshold beyond which the risk of moderate-to-severe [paravalvular regurgitation] is too high to attempt the procedure,” Dr. Raggi says. 

Going forward, Dr. Block said, design improvements already being incorporated in newer-generation valves will drastically reduce the issue of paravalvular regurgitation. 

Note: Several co-authors of the paper are faculty members of the Cardiovascular Research Foundation, which owns and operates TCTMD.

 


Sources: 
1. Khalique OK, Hahn RT, Gada H, et al. Quantity and location of aortic valve complex calcification predicts severity and location of paravalvular regurgitation and frequency of post-dilation after balloon-expandable transcatheter aortic valve replacement. J Am Coll Cardiol Interv. 2014;7:885-894.

2. Raggi P. Paravalvular regurgitation and post-deployment balloon dilation after transcatheter aortic valve replacement: can we predict and prevent [editorial]? J Am Coll Cardiol Interv. 2014;7:895-897.

Related Stories

Disclosures
  • Dr. Kodali reports receiving consulting fees from Edwards Lifesciences and Medtronic and serving on advisory boards of Paieon Medical, St. Jude Medical, and Thubrikar Aortic Valve and the steering committee of Claret Medical.
  • Drs. Khalique and Raggi report no relevant conflicts of interest.
  • Dr. Block reports holding equity in Direct Flow Medical.

Comments